Madrigal Pharmaceuticals (MDGL) Change in Receivables (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Change in Receivables for 5 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Receivables fell 72.17% year-over-year to $5.0 million; the TTM figure through Jun 2026 stood at $113.1 million (up 56.33% YoY), while the FY2025 annual figure was $80.7 million, up 49.85% from the prior year.
• Change in Receivables eased to $5.0 million in Q2 2026 per MDGL's latest filing, from $52.9 million in the prior quarter.
• Across five years, Change in Receivables topped out at $52.9 million in Q1 2026 and bottomed at $5.0 million in Q2 2026.
• Historically, Change in Receivables has averaged $21.4 million across 3 years, with a median of $21.2 million in 2025.
• On a YoY basis, Change in Receivables climbed as much as 595.24% in 2026 and fell as far as 72.17% in 2026.
• Madrigal Pharmaceuticals' Change in Receivables stood at $23.4 million in 2024, then declined by 9.28% to $21.2 million in 2025, then slumped by 76.62% to $5.0 million in 2026.
• Business Quant data shows MDGL's Change in Receivables at $5.0 million in Q2 2026, $52.9 million in Q1 2026, and $21.2 million in Q4 2025.